What Is Your Medspa Worth? Valuation & EBITDA Multiples

Small, single-location practices (typically $300K–$1M EBITDA) trade at 3–5x EBITDA, sometimes lower if revenue is heavily dependent on one provider or lacks systems. Established, multi-location or high-revenue single practices ($1M–$3M EBITDA) command 6–9x EBITDA, reflecting proven operations, recurring patient base, and some scalability. Larger platforms and roll-up targets ($3M–$10M+ EBITDA) see 10–15x EBITDA or higher, particularly if they have:

• Recurring revenue (membership, subscription models)
• Multiple locations or franchisable systems
• Experienced management team beyond the founder
• Strong gross margins (typically 65–75% in medspas)
• Diversified revenue (toxin, filler, devices, wellness)

Exceptional platforms with $10M+ EBITDA, national footprint, and institutional-grade operations have commanded multiples in the 15–20x range in recent PE-backed roll-ups, though this is rare and depends on growth rate and market conditions.

Recurring revenue and patient retention are the biggest levers. A practice with 60%+ of revenue from existing patients on regular toxin or filler schedules commands a premium over one dependent on one-time procedures or new-patient acquisition. Gross margin matters intensely: practices with strong negotiating power on product cost (via Alle, Aspire, or Evolus Rewards loyalty programs) and high-margin services (injectables over devices) trade higher. Provider dependency cuts the multiple sharply—if the owner is the only injector and the practice loses 40% of revenue if they leave, expect a 1–2x haircut. Systems and documentation (EHR, CRM, patient outcome tracking) signal scalability. Location and real estate (owned vs. leased, lease terms remaining) affect buyer confidence in continuity. Regulatory and compliance posture matters: clean state-board record, proper supervision structures, no FDA warning letters, and documented scope-of-practice compliance reduce buyer risk. Conversely, high customer-acquisition cost, thin margins, reliance on a single product line (e.g., only Botox), or high staff turnover compress multiples.

All-cash deals at a stated multiple are rare in medspas. Most transactions involve a mix of cash at close and earnout, typically structured as:

• 60–70% cash at signing, based on agreed EBITDA multiple
• 30–40% earnout over 1–3 years, contingent on hitting revenue or EBITDA targets post-acquisition

Earnouts protect the buyer if the practice loses patients or providers post-close; they also incentivize the seller to stay engaged. Seller rollover equity (the seller takes a minority stake in the buyer's platform) is common in roll-up scenarios—you get partial cash, partial equity, and upside if the platform is sold or goes public. Earnout clawback language is critical: understand what happens if EBITDA misses, whether the buyer can adjust for one-time costs, and whether you have dispute resolution. Non-compete and employment terms are standard: expect 2–5 year non-competes and a 1–3 year employment agreement (often with a base salary and bonus tied to performance). Seller financing is less common but appears in smaller deals where the buyer (often a DSO or smaller PE fund) needs to preserve cash.

Buyers normalize EBITDA by adding back owner compensation, one-time costs, and adjusting for what they believe is market-rate staffing. A typical calculation:

• Net income (from tax return or P&L)
• + Interest, taxes, depreciation, amortization
• + Owner salary (if you pay yourself below market, they add back the difference)
• + One-time costs (legal, consulting, relocation)
• – Excess owner perks (car, country club, personal travel)
• = Adjusted EBITDA

Buyers often use trailing twelve months (TTM) or last full fiscal year as the baseline, then apply a growth rate or average if you've shown upward trajectory. Seasonality matters: practices with strong Q4 (holiday gift certificates, New Year's resolutions) may be valued on a normalized annual run-rate. Insist on seeing the buyer's EBITDA calculation before signing; discrepancies here are where deals fall apart or sellers feel shortchanged.

A serious offer will include:

• Purchase price (stated as a multiple of EBITDA, e.g., "6.5x TTM EBITDA")
• EBITDA calculation (the buyer's normalized number—verify this)
• Cash at close (usually 60–70% of total consideration)
• Earnout terms (amount, duration, milestones, and clawback language)
• Seller rollover (if applicable—equity stake, vesting schedule)
• Reps and warranties (your promises about the business; breaches can trigger indemnification)
• Non-compete and employment agreement (term, salary, bonus structure, termination provisions)
• Closing conditions (due diligence, financing, regulatory approval)
• Timeline (expected close date, exclusivity period)

Red flags: vague EBITDA definitions, earnout targets that seem unachievable, excessive clawback language, or a non-compete that's too broad geographically or temporally. Hire a healthcare M&A attorney—the cost ($15K–$40K) is trivial relative to a $2M–$10M transaction. Have them review the purchase agreement, not just the term sheet.

The medspa M&A market has remained active despite broader healthcare consolidation headwinds. PE-backed platforms (backed by firms focused on healthcare services) continue to acquire single and multi-location practices, though they are more disciplined on valuation post-2024. Strategic buyers (large DSOs, dermatology groups, hospital systems) are selective, favoring practices with strong injector talent and recurring revenue. Founder-led roll-ups (where a successful medspa owner builds a platform by acquiring peers) have slowed slightly due to higher debt costs and tighter lending standards. Earnout realization has been mixed: some sellers have hit targets and received full consideration; others have faced revenue headwinds (patient attrition, competitive pressure, GLP-1 weight-loss trends affecting filler demand) and earned less than expected. Valuations have moderated from 2021–2022 peaks but remain healthy for practices with strong fundamentals. Recurring revenue and gross margin are the two metrics that matter most to buyers right now.

If you're thinking about a sale or want to maximize value:

• Clean up financials: Use consistent accounting, separate owner perks, and document all add-backs. Buyers will dig here.
• Build recurring revenue: Shift toward membership or subscription models; this increases multiple by 1–2x.
• Reduce provider dependency: Cross-train staff, document protocols, and establish that the practice can run without you for extended periods.
• Document systems: EHR, patient CRM, marketing spend, staff org chart, and supplier contracts. Buyers want to see scalability.
• Maintain compliance: Ensure all injectors are properly credentialed, supervised per state law, and documented. A state-board complaint can tank a deal.
• Diversify revenue: Don't rely on one product (Botox) or one service (injectables). Add devices, wellness, or complementary services.
• Stabilize or grow EBITDA: Buyers value growth; a practice with flat or declining EBITDA trades at a discount. Focus on patient retention and margin expansion in the 12–18 months before a sale.

If you're not planning to sell, these steps still improve your practice's resilience and profitability.